SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Zontivity® (voranaxar)

Diag Hequestea	Zonervity (vorapaxar)				
MEMBER & PRE	SCRIBER INFORMATION	N: Authorization	may be dela	yed if incomplete.	
Member Name:					
Member Sentara #:		Date of Birth:			
Prescriber Name:					
Prescriber Signature:		Date:			
Office Contact Name:					
Phone Number:	nber: Fax Number:				
DEA OR NPI #:					
	TION: Authorization may be de	<u> </u>			
Dosing Schedule:		_ Length of The	erapy:		
Diagnosis:		ICD Code, if applicable:			
Weight: Date:					
	Zontivity® is not to be u	sed as monot	therapy		
	CRIA: Check below ALL that apg labs or chart notes (if required) m				
• Prescriber is:	vascular specialist	□ cardi	ologist		
☐ Has patient had	a myocardial infarction? (MI)	□ Yes □	No		
1. Does patient	have peripheral arterial disease? (F	PAD)		□ Yes □ No	
2. Has patient had a previous stroke?				□ Yes □ No	
3. Has patient had a previous transient ischemic attack? (TIA)				□ Yes □ No	
4. Has patient had a previous intracranial hemorrhage?				□ Yes □ No	

** Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

^{*}Approved by Pharmacy and Therapeutics Committee: 9/18/2014
REVISED/UPDATED/REFORMATTED: ++/24/2014; +2/12/2014; 5/22/2015; +2/29/2015; +2/20/2016; 8/24/2017; 6/18/2019; 10/27/2023